FRI0074 Factors associated with the developement of severe respiratory infections in patients with rheumatoid arthritisincluded in a vaccination program. (12th June 2018)

• Record Type: Journal Article
• Authors: Domínguez Casas, L.C.; Rodriguez-Cundin, P.; Calvo-Río, V.; Vegas-Revenga, N.; Portilla, V.; Antolin, F.; Rebollo-Rodrigo, M.; Corrales, A.; Palmou-Fontana, N.; Prieto-Peña, D.; Calderón Goercke, M.; Blanco, R.; Gonzalez-Gay, M.
• Is Part Of: Annals of the rheumatic diseases. Volume 77(2018)Supplement 2
• Page Start: 583
• Page End: 583
• Publication Date: 2018-06-12
• Subjects: Rheumatism -- Periodicals; 616.723005
• DOI: 10.1136/annrheumdis-2018-eular.7393
• Languages: English
• ISSNs: 0003-4967

Abstract

Abstract : Background: Rheumatoid arthritis (RA) patients are at increased risk of severe infections. Besides the disease itself, the immunosuppressive treatment appears to play an important role in the risk of infections. Vaccination programs are designed to decrease the risk of infections in these patients. Objectives: Our aim was to assess the incidence of severe respiratory infections in patients with RA and to determine the underlying risk factors for the development of these complications. Methods: Retrospective study of 401 patients diagnosed with RA who were invited to participate in a vaccination program from October 2011 to October 2016. The follow-up was made until June 2017 with a minimum follow-up period of 8 months and maximum of 5.5 years. Information on severe respiratory infection episodes was retrieved from the hospital medical records. Serious infections were defined as those that required hospitalisation or at least one dose of intravenous antibiotic treatment at the emergency room. Only 7 patients refused vaccination (2%). Information was not obtained in 4 of the remaining 394 patients. Therefore, these 4 patients were not included in the assessment. Results: 390 patients (307♀/83 ♂) average age 61.28±12.9 years were vaccinated a followed-up. The main features at the time of vaccination were: median disease duration (4 years), positive rheumatoid factor (56.7%), subcutaneous nodules (4.9%), erosive arthritis (36.9%), pulmonary fibrosis (3.8%), Sjögren syndrome (5.1%) other extraarticular manifestations (14.6%) and rheumatoid vasculitis (5.6%). Most patients had received immunosuppressive drugs before the vaccination program. The most frequently used were systemic corticosteroids (n=228), methotrexate (n=362) and biologic agents (40.3%). During the follow-up, 42 patients (10.7%) had required hospital admissions due to infections, 17 of them were severe respiratory infections (4.35%) The remaining 25 admissions were in the setting of urinary tract infections (n=12), intraabdominal infections (n=7), skin and soft tissues (n=12) and articular (n=1). Also 12 of these patients had a zoster herpes. The presence of anti-citrullinated protein antibodies (ACPA) was associated with an increased frequency of admissions due to these infections. It was also the case for the presence of a history of biologic therapy prior to vaccination. No association of severe respiratory infection with rheumatoid factor, erosions or pulmonary fibrosis was found. ( table 1) . Conclusions: Vaccinated patients with RA present a low incidence of severe respiratory infections. Positivity for ACPA and the use of biologics prior to vaccination are associated with increased risk of severe respiratory infections in these patients. Therefore, vaccination should be performed prior to the onset of biologic treatment. Disclosure of Interest: None declared